Showing 1 - 5 of 5
Persistent link: https://www.econbiz.de/10001653620
Persistent link: https://www.econbiz.de/10003320101
The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the...
Persistent link: https://www.econbiz.de/10010528451
Persistent link: https://www.econbiz.de/10010378714
Considerable variance was observed in the levels of additional benefit reported by pharmaceutical manufacturers, IQWiG and G-BA. The areas of disagreement included ACT selection, definition of subgroups and patient-relevant endpoints, and classification and balancing of adverse events. </AbstractSection>...
Persistent link: https://www.econbiz.de/10010993901